SCHEMBL6418374

SCHEMBL6418374

N/N=C(\c1cccc(O)c1)c1nc2nonc2nc1NCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.40
KDR P35968 1/20 0.40
CSNK1D P48730 2/20 0.37
LDHA P00338 1/20 0.36
LDHB P07195 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
RXFP1 Q9HBX9 1/20 0.35
IDO1 P14902 1/20 0.35
ACHE P22303 1/20 0.35
APP P05067 2/20 0.34
KDM4E B2RXH2 2/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
BLM P54132 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6418383 1.00 EGFR (0.40) EGFRKDRCSNK1DLDHALDHB
SCHEMBL6416068 0.89 LDHA (0.46) LDHALDHBKMT2AACHEAPP
SCHEMBL6416054 0.89 LDHA (0.46) LDHALDHBKMT2AACHEAPP
SCHEMBL6414153 0.88 STAT6 (0.38) EGFRKDRCSNK1DMEN1KMT2A
SCHEMBL6414138 0.88 STAT6 (0.38) EGFRKDRCSNK1DMEN1KMT2A
SCHEMBL6415718 0.84 EGFR (0.39) EGFRKDRMEN1KMT2ARXFP1
SCHEMBL6415738 0.84 EGFR (0.39) EGFRKDRMEN1KMT2ARXFP1
SCHEMBL6414695 0.84 PIM1 (0.40) MEN1KMT2AMAPTHTTSMN1; SMN2
SCHEMBL6414707 0.84 PIM1 (0.40) MEN1KMT2AMAPTHTTSMN1; SMN2
SCHEMBL6433104 0.83 ALDH1A1 (0.41) LDHALDHBMEN1KMT2AACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 EGFR 1083/4885KDR 894/4885CSNK1D 1109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.